Abstract:ObjectiveTo evaluate the acute and long-term effect of nicorandil on patients with acute ST segment elevation myocardial infarction (ASTEMI) undergoing percutaneous coronary intervention (PCI).MethodsWe searched the published data relevant to randomized controled trials (RCTs) comparing treatment with nicorandil prior to reperfusion therapy with controls (placebo or no nicorandil) in patients with AMI undergoing primary PCI from the data source of PubMed, Cochrane Library, CNKI, WANGFANG, and VIP databases up to May. 2014. After quality assessment, al included RCTs were analyzed by Review Manger 5.1 software.Results14 trials involving 1 930 patients were included into this Meta-analysis. The results showed that Nicorandil significantly reduced the incidence of TIMI flow grade less than 2 (RR: 0.49; 95%CI: 0.36-0.65) and the corrected TIMI Frame Count (CTFC) mean difference(MD:-5.40; 95%CI:-7.18--3.68), reduced the incidence of reperfusion arrhythmia (RR: 0.54; 95%CI: 0.37-0.78) and enhanced left ventricular ejection fraction (LVEF)(%) within 6 months (MD: 5.98; 95%CI: 3.53-8.43), reduced the incidence of the primary end point events (including cardiovascular death and unplanned hospital admission of congestive heart-failure(CHF)(RR: 0.42; 95%CI: 0.29-0.59). Nicorandil did not change the peak creatine kinase (CK) level (MD:-115.94; 95%CI:-353.77-121.90). ConclusionsNicorandil administration prior to reperfusion is helpful for the improvement of coronary reflow and inhibition of reperfusion arrhythmias. It improves left ventricular function in AMI patients treated with primary PCI. Moreover, Nicorandil reduces the incidence of the primary end point events and improves the long-term prognosis.

Impact of nicorandil on acute and long-term prognosis in patients with acute myocardial infarction undergoing percutaneous coronary intervention：Meta-analysis